<DOC>
	<DOCNO>NCT00414388</DOCNO>
	<brief_summary>The primary objective study evaluate safety combine Sorafenib chemotherapy ( mitoxantrone docetaxel ) patient AIPC .</brief_summary>
	<brief_title>Sorafenib Overcome Resistance Systemic Chemotherapy Androgen-independent Prostate Cancer</brief_title>
	<detailed_description>Patients AIPC progress despite systemic chemotherapy offer participation study . Patients relapse progress shortly ( within 12 week ) discontinuation chemotherapy either docetaxel/prednisone mitoxantrone/prednisone also offer participation trial . Enrolled patient receive sorafenib per protocol define dose . Sorafenib administer combination last chemotherapy utilize . If disease progression 6 cycle , chemotherapy stop Sorafenib may continue disease progression .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Age &gt; 18 year old Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 . Patients know diagnosis prostate cancer regardless Gleason grade . Patients AIPC . Adequate bone marrow , liver renal function assess : Hemoglobin &gt; 9.0 g/dl absolute neutrophil count ( ANC ) &gt; 1,000/mm3 Platelet count &gt; 75,000/mm3 Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN ( &lt; 5 x ULN patient liver involvement ) . international normalized ratio ( INR ) &lt; 1.5 Prothrombin time ( PT ) /partial thromboplastin time ( PTT ) within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . Creatinine &lt; 1.5 x ULN Transfusions use growth factor ( red white cell ) allow Patients must receive either docetaxel mitoxantrone chemotherapy regimen Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . Patients must progress receive systemic chemotherapy AIPC . Patients could progress within 12 week last systemic chemotherapy administration . The definition progression define follow : 1For patient receive systemic chemotherapy ( one criterion sufficient ) : Increase prostatespecific antigen ( PSA ) 25 % previous value . This repeat within 3 week ( patient chemotherapy ) confirm PSA decrease . For patient visceral disease , radiographic evidence progression standard Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ( regardless PSA value ) . For patient bone disease , progression whole body bone scan ( 2 new lesion ) sufficient fulfill definition progressive disease , regardless PSA value visceral disease status . 2For patient receive chemotherapy previously ( Both criterion need ) : Not 12 week elapse since last chemotherapy administration Either biochemical progression ( 25 % increase PSA confirm repeat analysis within 3 week ) , OR radiographic progression ( RECIST criterion visceral disease patient OR 2 lesion whole body bone scan ) Cardiac disease : Congestive heart failure &gt; class II New York Heart Association 9NYHA ) . Patients must unstable angina new onset angina myocardial infarction within past 6 month . Known brain metastasis . Patients neurological symptom must undergo CT scan MRI brain exclude brain metastasis . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Patients history chronic well control atrial fibrillation allow . Betablockers , calcium channel blocker , digoxin consider antiarrhythmic . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Sorafenib contraindicate patient know severe hypersensitivity sorafenib excipients . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. Active clinically serious infection &gt; Common Toxicity Criteria Adverse Effects ( CTCAE ) Grade 2 . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug . Serious nonhealing wound , ulcer , bone fracture . Evidence history bleed diathesis uncontrolled coagulopathy . Major surgery , open biopsy significant traumatic injury within 4 week first study drug . Use St. John 's Wort rifampin ( rifampicin ) . Known suspected allergy sorafenib agent give course trial . Any condition impair patient 's ability swallow whole pill .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>AIPC</keyword>
</DOC>